Genmab partner's Darzalex sales almost reach analyst estimates
![Photo: George Frey/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/15616450/72oxg6/ALTERNATES/schema-16_9/20220722-213856-4-8640x5760ma.jpg)
Johnson & Johnson’s sales of Darzalex in the first quarter almost aligned with analysts’ expectations. This is evident in J&J’s Q1 report and is further confirmed in a press release by the Danish biotech company that developed the cancer drug, Genmab, which receives royalties on sales.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab enters multiyear antibody partnership with Argenx
For subscribers
Genmab's conservative outlook predicts duller growth in 2023
For subscribers